c-Myb Is Critical for B Cell Development and Maintenance of Follicular B Cells  by Thomas, Matthew D. et al.
Immunity, Vol. 23, 275–286, September, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.immuni.2005.08.005
c-Myb Is Critical for B Cell Development
and Maintenance of Follicular B CellsMatthew D. Thomas,1,3 Christopher S. Kremer,1
Kodi S. Ravichandran,1 Klaus Rajewsky,2
and Timothy P. Bender1,*
1The Department of Microbiology
P.O. Box 800734
University of Virginia Health System
Charlottesville, Virginia 22908
2Center for Blood Research
Harvard Medical School
300 Longwood Avenue
Boston, Massachusetts 02115
Summary
The c-Myb transcription factor is crucial during defin-
itive hematopoiesis. However, the embryonic lethality
of Myb traditional null mutations has precluded analy-
sis of c-Myb function in lymphocytes. Using tissue-
specific inactivation at the Myb locus, we demon-
strate that loss of Myb causes a partial block during B
cell development at the pro-B to pre-B cell transition,
resulting in greatly decreased output of new B cells
from the bone marrow. Furthermore, we demonstrate
that Myb is not essential for the proliferation of sple-
nic B cells, but that loss of c-Myb function prevents
normal B cell homeostasis due to decreased splenic
B cell survival. Decreased survival is accompanied by
hyporesponsiveness to the B cell survival factor
BLyS (also termed BAFF), decreased expression of
the BLyS receptor 3 (BR3), and altered regulation of
PKC nuclear accumulation. Thus, c-Myb is important
during multiple stages of B-lymphopoiesis.
Introduction
B cell development is characterized by the sequential
expression of cell-surface markers and the ordered re-
arrangement of immunoglobulin (Ig) heavy and light
chain gene segments (Loffert et al., 1994). Hematopoi-
etic stem cells (HSC) give rise to progenitor B cells (pro-
B cells) that undergo rearrangement of the Ig heavy
chain (H chain) locus. Successful H chain rearrange-
ment leads to expression of  H chain, which associates
with surrogate light chain (L chain) and the signaling
molecules Ig-α and Ig-β to form the pre-BCR complex.
Signaling through the pre-BCR results in clonal expansion
of cytoplasmic + cells and differentiation to the small
pre-B cell stage of differentiation. Small pre-B cells un-
dergo rearrangement at the Ig L chain loci. Pre-B cells
that produce L chain, paired with the  heavy chain,
express membrane bound IgM (mIgM) and are referred
to as immature (IM) B cells.
IM B cells emigrate from the bone marrow (BM) to the
spleen, where they progress through transitional stages*Correspondence: tpb3e@virginia.edu
3 Present address: University of Pennsylvania, 230 John Morgan
Building, 36th and Hamilton Walk, Philadelphia, Pennsylvania 19104.(Allman et al., 2001; Loder et al., 1999). Transitional (TR)
B cells that successfully compete for entry into splenic
follicles give rise to follicular (FO) B cells, which com-
pose the majority of mature B cells (Martin and Kear-
ney, 2000). Marginal zone (MZ) B cells are thought to
be derived from TR B cells (Saito et al., 2003). Finally,
the spleen, peritoneal, and pleural cavities contain B1 B
cells (Martin and Kearney, 2001). Maintenance of each
peripheral B cell subset is controlled by the availability
of resources, the local environment, and interactions
with other cell types (Gaudin et al., 2004).
The Myb protooncogene encodes a nuclear, DNA
binding protein that functions as both a transcription
activator and repressor. HSC and progenitors of each
hematopoietic lineage express c-Myb, and the down-
regulation of Myb expression is associated with
hematopoietic maturation (Akashi et al., 2000). The pat-
tern of Myb expression suggested that it plays a signifi-
cant role in regulating hematopoiesis and this has been
supported experimentally. Most significantly, Myb-defi-
cient embryos develop normally to day 14, after which
they die with severely disrupted patterns of erythroid
and myeloid development (Mucenski et al., 1991). How-
ever, it is not clear whether Myb mediates its affects on
hematopoiesis at the level of proliferation, survival, or
differentiation (Oh and Reddy, 1999).
B cell progenitors and mature B cells contain Myb
mRNA and c-Myb protein (Golay et al., 1992; Morrow
et al., 1992). Cloned murine tumor cell lines represent-
ing the pro-B and pre-B cell stages of development
contain 50-fold more Myb mRNA than cell lines repre-
senting the IM, mature, and plasma cell stages of differ-
entiation (Bender and Kuehl, 1987), and Myb expres-
sion is downregulated in a leukemic murine pre-B cell
line after being induced to express mIgM (Bender and
Kuehl, 1987), suggesting that downregulation of Myb
expression may be associated with transition from the
pre-B to IM B cell stage of differentiation. Myb expres-
sion increases after activation of mature B cells (Golay
et al., 1992), and increased Myb expression is associ-
ated with transition from G1 to S phase during the cell
cycle in B cells (Catron et al., 1992; Golay et al., 1992;
Thompson et al., 1986). Myb null embryonic stem cells
are unable to give rise to B lineage cells in the Rag1–/–
blastocyst complementation system, supporting a role
for c-Myb during B-lymphopoeisis (Allen et al., 1999).
We have used cell-specific deletion to examine c-Myb
function during B-lymphopoiesis and find that loss of
c-Myb results in a partial block to B cell development
at the pro-B to pre-B cell transition and a nearly 90%
reduction in the number of IM B cells in the BM. Despite
decreased output of new B cells from the BM, spleens
of mutant mice contain nearly 50% of the normal com-
plement of B cells. c-Myb-deficient B cells respond
poorly to BLyS (also called BAFF), which is a major de-
terminant of naive B cell survival (Mackay et al., 2003),
and expression of BR3 (also called BAFF-R) is reduced
in c-Myb-deficient B cells. Further, c-Myb-deficient B
cells exhibit abnormal regulation of PKCδ nuclear accu-
mulation after treatment with BLyS. These results dem-
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stages of B-lymphopoiesis.
Results
c-Myb Is Required for Normal B Cell Development
Pro-B and pre-B cells contain abundant Myb mRNA,
while IM and recirculating B cells contain w80% less
Myb mRNA (Figure 1A). To determine whether Myb is
important during B cell development, we targeted the
mouse Myb locus with loxP sites for deletion by Cre
recombinase (Bender et al., 2004). Mice were con-
structed that carried a loxP targeted (Mybf) or prede-
leted (Mybd) Myb allele (Figure 1B), and deletion of the
targeted portion of the Myb locus creates a null allele
(Bender et al., 2004). To direct Cre expression to de-
veloping B lineage cells, we crossed Mybf/w or Mybd/w
mice to CD19-cre mice that express Cre under the tran-
scriptional control of the B lineage-specific CD19 regu-
latory sequences (Rickert et al., 1997). Cre expression
in CD19-cre mice is first detected in Fraction (Fr) B pro-
B cells. Mybf/w CD19-cre or Mybd/w CD19-cre mice
were then crossed to Mybf/f mice to produce Mybf/f
CD19-cre (f/f), Mybf/d CD19-cre (f/d), or Mybf/w CD19-
cre (f/w) control mice.
B cell development was analyzed in 8- to 10-week-
old f/d and control mice by flow cytometry (Figures 1C
and 1F). We detect no difference in the distribution of
BM B cell subsets between control Mybf/d, Mybf/w, or
Mybw/w mice (see Table S1 in the Supplemental Data
available with this article online), and a single Myb allele
is sufficient to support B cell development. BM from f/d
mice contained few mIgM+ B cells, and both IM and
recirculating B cell populations were decreased w80%
in f/d mice compared to controls. Similarly, the number
of pre-B cells was decreased 65% to 75%, but there
was no decrease in the number of pro-B cells in mutant
mice. The pro-B cell compartment can be further subdi-
vided into Fr A-C# based on surface expression of the
BP-1 and CD24 surface markers (Hardy et al., 1991).
BM from f/f and control mice contained Fr A-C# (Figure
1D). However, Fr C was reduced by w50% and Fr C#
was decreased 80% to 90% in f/f mice. To better under-
stand these results, we compared the efficiency of dele-
tion at the Myb locus in pro-B and pre-B cells from f/f
and f/d mice. Since Cre will be expressed only in CD19+
cells in CD19-cre mice, we sorted CD19+ pro-B cells
and pre-B cells from f/f and f/d mice (Figure 1E). The
floxed Myb allele was efficiently deleted in pro-B cells
but only inefficiently, if at all, in pre-B cells. The poor
deletion efficiency at the Myb locus in pre-B cells sug-
gests that c-Myb-deficient pro-B cells may fail to dif-
ferentiate from pro-B to pre-B cells and that c-Myb is
important for the maintenance of pre-B cells.
To determine how loss of Myb affects population ki-
netics, we analyzed BrdU labeling rates in BM B-lin-
eage subsets. Both control and c-Myb-deficient B cells
exhibited a renewal rate of w20% per day in the pro-B
cell compartment (Figure 1G), corresponding to a pro-
duction rate of 1–1.5 × 106 cells per day (Table 1). Pre-
B cells from f/f and f/d mice displayed a slightly de-
creased proportional labeling compared to controls
(29% versus 34%, respectively), but a 50% decrease in
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mre-B cell production compared to controls (3.7 × 106
ersus 7.4 × 106, respectively). Similarly, IM B cells from
/f and f/d mice displayed comparable proportional la-
eling with controls, while daily production was de-
reased to w30% of control levels (0.7 × 106 versus
.3 × 106, respectively). These results suggest that the
oss of Myb primarily affects the number of pre-B and
M B cells generated, but not residency time within their
espective pools. Since the residency time of pro-B
ells did not differ between mutant and control mice, it
ppears that c-Myb is not required for the maintenance
f CD19+ pro-B cells.
-Myb Is Required for the Normal Development
f Follicular and B-1 Peripheral B Cell Subsets
lthough the BM from f/f and f/d mice contained only
0% to 20% as many IM B cells as controls, we found
hat spleens from mutant mice contained w50% the
umber of CD19+ mIgM+ B cells as control animals (Fig-
res 1F and 2A). Serum from f/f and control mice con-
ained equivalent amounts of each Ig allotype (Figure
1), and f/f mice produced antigen-specific antibody
esponses to T cell-dependent and -independent anti-
ens that were comparable to controls (data not shown).
hen f/f and f/d splenic B cells were assessed for dele-
ion at the floxed Myb locus, >90% carried the deletion,
emonstrating that B cells in mutant mice did not rep-
esent outgrowth of B cells retaining a functional Myb
llele (Figure 2B). We next examined the distribution of
plenic B cell subsets of f/d and control mice. Loder
nd colleagues identified two TR B cell subsets, T1 and
2, in addition to FO and MZ B cells (Loder et al., 1999).
hese four subsets can be identified in the spleen
ased on expression of CD23, CD21, IgM, and IgD
Loder et al., 1999; Martin and Kearney, 2002). The
umber of T1, T2, and FO B cells was decreased in
pleens from f/d mice compared to controls (Figures
C, 2D, and 2G). In contrast, we did not find decreased
umbers of MZ B cells, suggesting that c-Myb may be
ore important for the development or maintenance of
R and FO B cells than MZ B cells. TR, FO, and MZ B
ells contain similar amounts of Myb mRNA, and the
loxed Myb allele is efficiently deleted in each subset
Figure S2). Allman and colleagues have identified three
R B cell populations based on expression of the AA4.1
urface marker (Allman et al., 2001). We found that all
hree AA4.1+ TR B cell subsets and the FO B cell subset
ere decreased in size, but there was little effect on
he number of MZ B cells (Table S2).
The percentage of CD5+ peritoneal B cells was
85% reduced in f/f mice compared to controls (Figure
E). Further analysis of B cell subsets in the peritoneal
avity demonstrated that the percent of both the
220hiCD19lo B2 B cell and the B220loCD19hi B1 B cell
ubsets were decreased in f/f mice compared to con-
rols (Figure 2F). However, gating on the B220loCD19hi
eritoneal cells demonstrated that the percentage of
D5+ B1a B cells was reduced to a greater extent than
he percentage of CD5lo/− B1b B cells. Thus, c-Myb ap-
ears to be important for the development and/or
aintenance of B1 B cells as well as TR and FO B cells.
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277Figure 1. Loss of c-Myb Results in Aberrant B Cell Development
(A) Bone marrow (BM) and splenic CD19+ B cells were isolated by flow cytometry based on expression of B220, IgM, CD43, and CD19. Myb
mRNA was measured by semiquantitative RT-PCR. Results are the average of two independently sorted pools of cells from C57BL/6 mice.
(B) Schematic representation of (1) the Myb targeted allele, (2) the floxed Myb (Mybf) allele after deletion of the neomycin resistance gene,
and (3) expression of Cre in vitro or in vivo, which generates the Myb-deleted (Mybd) allele.
(C) BM cells were stained for surface expression of B220, IgM, and CD43. Numbers are the percent of total nucleated BM cells in each gate
or of cells in the gate indicated in brackets above the plots. Plots are representative of more than 50 control and mutant mice. f/w, Mybf/w
CD19-cre; f/d, Mybf/d CD19-cre.
(D) Top tier of plots presents the distribution of B220 and CD43 on live BM cells from control and f/d mice. Numbers are the percent of total
nucleated BM cells in each gate or of cells in the gate indicated in brackets above the plots.
(E) Genomic DNA was isolated from CD19+ pro- and pre-B cells from mice of the indicated genotypes and analyzed by PCR for the presence
of the floxed (f) and deleted (d) Myb alleles.
(F) Numbers of pro-B cells, pre-B cells, IM B cells, and mature recirculating B cells in the BM, as well as B cells in the spleen. Mean and SD
of BM cells from a minimum of 11 mice and spleen cells from 10 mice are shown. *p < 0.01, **p < 0.001, ***p < 0.0001.
(G) Renewal and production rates of B cell progenitor pools. f/w (squares) or f/f and f/d (circles) mice were injected with BrdU, and BM was
harvested at the indicated times and stained for surface phenotype and BrdU incorporation. Each point represents an individual mouse. Solid
and dashed lines are those determined by linear regression for f/w or f/f and f/d, respectively.c-Myb Is Not Required for Proliferation
of Peripheral B Cells
c-Myb-deficient B cells were large as measured by in-
creased forward scatter, and they displayed increasedsurface expression of CD69 and MHC Class II (Figure
3A), similar to the activated phenotype described for
B cells undergoing lymphopenia-induced homeostatic
proliferation (Cabatingan et al., 2002; Hao and Rajew-
Immunity
278Table 1. Renewal and Production Rates of Marrow B Cell Subsets
Mybf/w CD19-cre Mybf/f CD19-cre
Pro Renewal rate (% of pool/day) 22.1 18.8
Production rate (cells/day × 106) 1.4 1.2
Pre Renewal rate (% of pool/day) 34.2 28.9*
Production rate (cells/day × 106) 7.4 3.7**
Immature Renewal rate (% of pool/day) 22.6 24.5
Production rate (cells/day × 106) 2.3 0.7**
The percentages of pro-B, pre-B, and immature B subsets were assessed by flow cytometry and multiplied by the Osmond estimate of total
marrow cells to obtain total numbers (Opstelten and Osmond, 1983). The regression coefficients of percent and absolute BrdU labeling versus
time provide estimates of renewal and production rates, respectively. *p < 0.02, **p < 0.01.sky, 2001). f/d or control mice were injected with BrdU,
and incorporation of BrdU was measured 24 hr later,
which is not sufficient time for B cells derived from pro-
liferating progenitor cells in the BM to migrate to the
spleen. Spleens from control mice had 6.2% ± 1.2%
BrdU-positive B cells versus 14.4% ± 4.4% in f/d
spleens (Figure 3B), suggesting that about twice as
many splenic B cells in f/d mice are proliferating com-
pared to control mice. Furthermore, nearly twice as
many splenic B cells from mutant mice have a >2N DNA
content than splenic B cells from control animals (data
not shown). To determine whether c-Myb-deficient B cells
can undergo homeostatic expansion in a lymphopenic
environment, we transferred purified, CFSE-stained c-Myb-
deficient or control B cells into Rag-1-deficient mice.
Ten days after adoptive transfer, the recovery of f/d B
cells was only 20% that of control B cells (Figure 3C).
A large proportion of both c-Myb-deficient and control
B cells completed multiple rounds of proliferation as
measured by CFSE dilution, suggesting that c-Myb-
deficient B cells are able to proliferate in response to a
lymphopenic environment (Figure 3D).
To differentiate between defects in survival or prolif-
eration, we examined the ability of c-Myb-deficient B
cells to proliferate in response to LPS, anti-CD40 plus
IL-4, or anti-IgM crosslinking. 3[H]-thymidine uptake as-
says suggested that c-Myb-deficient B cells prolifer-
ated to the same extent as control B cells in response
to these stimuli (Figure 4A). This response was not due
to proliferation of B cells that failed to delete Myb, since
nearly 100% of the cells had deleted the floxed allele
throughout the experiment (Figure 4B). Because f/f and
f/d mice have decreases in the number of TR and FO B
cells, but not MZ B cells, the relative sizes of the splenic
populations are altered, potentially resulting in skewed
responses to BCR crosslinking, as the B cell subsets
react differently to such stimuli (Rolink et al., 1998). This
is unlikely, as f/f and f/d mice and control mice contain
nearly identical percentages of B cells capable of prolif-
erating in response to BCR crosslinking (85% versus
78%), while all splenic B cells can respond to both anti-
CD40 and LPS (Rolink et al., 1998).
3[H]-thymidine assays only allow analysis of the B
cell population as a whole, so we examined prolifera-
tion at the single-cell level. CFSE-labeled B cells from
mutant and control mice responded similarly to LPS
plus IL-4, reaching the same number of maximum divi-
sions (Figure 4C). However, more complete analysis of
the data revealed an increase in responder frequency
of c-Myb-deficient B cells, such that a greater number
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if cells had responded to the stimulus by dividing at
east once after 48 hr in culture (Figure 4D). This was
ikely due to the increased number of proliferating B
ells in f/f mice compared to control mice. Interestingly,
y 96 hr, c-Myb-deficient B cells generated fewer
aughter cells than control B cells (Figures 4E). Compa-
able results were obtained in response to crosslinking
urface IgM (Figure S3). These findings suggested that
-Myb-deficient B cells can proliferate normally but
ay have a survival defect that decreases their likeli-
ood of undergoing multiple rounds of division.
We analyzed DNA content in f/d and control B cells
fter treatment with LPS plus IL-4 (Figures 4F and 4G).
t 24 hr poststimulation, more B cells were detected in
he S and G2/M stages of the cell cycle in f/d mice than
n controls as measured by number of cells with a >2N
NA content, consistent with our BrdU uptake experi-
ents and analysis of CSFE dilution (Figures 3B and
D). At 48 hr poststimulation, both c-Myb-deficient and
ontrol B cells appeared to contain comparable num-
ers of cells with a >2N DNA content. However, by 72
r the number of c-Myb-deficient B cells with a >2N
NA content was less than the controls and the number
f B cells with a sub 2N DNA content was greater than
he controls. These experiments are consistent with a
ypothesis that B cells in the spleen of f/d mice prolifer-
te in response to the lymphopenic environment but die
t a faster rate than B cells in control mice.
ncreased Apoptotic Cell Death
n c-Myb-Deficient B Cells
o determine whether the loss of c-Myb affects B cell
urvival, we used a TUNEL assay to identify apoptotic
cells in freshly isolated splenocytes. f/d mice con-
ained approximately 5-fold more TUNEL+ B cells than
ontrol mice (Figure 5A). The increased number of
poptotic cells was specific to B cells, as there were
o differences in TUNEL+ splenic T cells in these mice.
everal reports have suggested that Bcl-2 is a c-Myb
arget gene (Taylor et al., 1996) but c-Myb-deficient and
ontrol B cells contain equivalent amounts of Bcl-2 pro-
ein (Figure S4).
To determine whether increased cell death of c-Myb-
eficient B cells represented caspase-dependent apo-
tosis, we cultured freshly isolated c-Myb-deficient or
ontrol B cells in the absence of exogenous growth fac-
ors (Illera et al., 1993). TUNEL assay revealed a 2- to
-fold increase in the proportion of apoptotic c-Myb-
eficient B cells compared to control B cells after 4 hr
n culture (Figures 5B and 5D), and this increase was
c-Myb in B Cell Development and Homeostasis
279Figure 2. Loss of c-Myb Results in Fewer TR,
FO, and B1 B Cells, but Not MZ B Cells
(A) Splenocytes were analyzed through a live
lymphocyte gate to identify CD19+ B cells.
Numbers indicate percent of total live lym-
phocytes.
(B) Genomic DNA was isolated from purified
B or T cells of mice with the indicated geno-
types, and Southern blotting identified the
12.5 kb floxed allele, the 11.5 kb wild-type
allele, and the 10 kb deleted allele.
(C) Total nucleated splenocytes were stained
for surface expression of CD23, CD21, IgM,
and IgD and analyzed to identify T1 (CD23−
IgDloIgMhiCD21−) and MZ (CD23−IgDloIgMhi
CD21+) B cells. Numbers are the percent of
total live lymphocytes in each gate or of cells
in the gate indicated in brackets above the
plots.
(D) Total nucleated splenocytes were stained
for surface expression of CD23, CD21, IgM,
and IgD and analyzed to identify T2 (CD23+
IgDhiIgMhiCD21+) and FO (CD23+IgDhiIgMlo
CD21+) B cells. Numbers represent the per-
cent of total live lymphocytes in each gate or
of cells in the gate indicated in brackets
above the plots.
(E) Peritoneal cells were analyzed to identify
IgM+CD5+ B1 B cells. Numbers indicate per-
cent of gated cells.
(F) Peritoneal cells were analyzed to identify
B220hiCD19lo B2 cells or B220loCD19hi B1
cells. B1a cells are CD5+ while B1b cells are
CD5lo/−. Numbers represent the percent of
total live lymphocytes in each gate or of cells
in the gate indicated in brackets above the
plots.
(G) Numbers of T1, T2, MZ, and FO B cells
in the spleen. Mean and SD of cells from a
minimum of 15 mice are shown. *p < 0.035,
**p < 0.015, ***p < 0.0002.abrogated in the presence of the pan-caspase inhibitor
Z-VAD(OMe)-FMK (Figures 5C and 5D). Surprisingly,
c-Myb-deficient B cells cultured for 24 hr died at the
same rate as B cells from control mice (Figure 5E). We
next identified apoptotic cells using the differential up-
take of Hoechst 33342 and propidium iodide (Lee and
Shacter, 2001) to confirm this result (Figure 5F). Analy-
sis of DNA fragmentation during these experiments fur-
ther supports this observation (Figure S5).
Increased death of c-Myb-deficient B cells in vivocould reflect an inability to respond to homeostatic sur-
vival signals or a defect in the basic metabolic pro-
cesses that maintain survival. The latter possibility sug-
gests the cells should continue to die at an accelerated
rate in vitro. c-Myb-deficient B cells cultured for 4 hr
contain more apoptotic cells than control mice, but af-
ter 24 hr of culture, c-Myb-deficient B cells and control
B cells died at an equivalent rate. This suggests that
increased cell death of c-Myb-deficient B cells is likely
due to the failure to receive appropriate survival signals
Immunity
280Figure 3. c-Myb-Deficient B Cells Display an Activated Phenotype
and Can Proliferate In Vivo
(A) Histograms present forward scatter (FSC), surface expression
of CD69 and MHC Class II on CD19+ splenocytes. Heavy lines rep-
resent f/d mice and light lines represent control mice. Results are
representative of a minimum of 10 mutant and 10 control mice.
(B) BrdU uptake in CD19+ splenocytes was analyzed 24 hr after
injection with BrdU. Results are representative of 6 control and 6
f/d mice.
(C) Histogram presents the number of donor-derived B cells
(CD19+κ+) recovered from Rag1–/– hosts 10 days postinjection.
Data are representative of two independent experiments. Error bars
represent standard deviation (SD) of the mean.
(D) CFSE-stained CD43− B cells from f/d or control mice were in-
jected into Rag1–/– hosts, and 10 days later CD19+κ+ splenic B cells
were examined for CFSE fluorescence. Numbers indicate percent
of gated cells. Data are representative of two independent experi-
ments.
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ain the mouse. Taken together, these data demonstrate
that the loss of c-Myb in splenic B cells results in in-
creased apoptosis and suggest that f/f and f/d mice fail
to fill the splenic B cell compartment due to an inability
to respond to survival signals in vivo.
c-Myb-Deficient B Cells Are Hyporesponsive
to BLyS
To determine whether c-Myb-deficient B cells can re-
spond normally to survival signals, we stimulated c-Myb-
deficient and control B cells with anti-CD40 and as-
e
d
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(
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w
(
T
v
layed proliferation by CFSE dilution and survival using
opro-3 (Foy et al., 1993). Interestingly, we found no
ifference in proliferation (Figure S3) or percent live cell
ecovery (74 ± 6 and 71 ± 4 for control and c-Myb-
eficient B cells, respectively) after stimulation with
nti-CD40. Thus, c-Myb-deficient B cells are capable
f responding to survival signaling through CD40, pro-
iding further support for the hypothesis that c-Myb-
eficient B cells do not have a basic metabolic defect
hat results in poor survival but instead fail to respond
o homeostatic survival signals in the mouse.
BLyS and BR3 are crucial for B cell homeostasis, and
oss of either protein results in a profound decrease in
eripheral B cell number (Sasaki et al., 2004; Schie-
ann et al., 2001). To determine whether c-Myb-defi-
ient B cells respond to BLyS, we cultured purified
plenic B cells with medium alone, with BLyS, or with
L-4 (Illera et al., 1993). In medium alone, c-Myb-defi-
ient and control B cells died at a similar rate (Figure
A). However, when cultured with BLyS, c-Myb-defi-
ient B cells responded poorly compared to controls at
ach time point. This response was specific to BLyS,
s c-Myb-deficient B cells displayed normal respon-
iveness to IL-4 at 72 and 96 hr. To eliminate the possi-
ility that the poor BLyS response was due to the al-
ered distribution of B cell subsets in f/f and f/d mice,
e assessed the response of CD23+ peripheral B cells,
hich consist almost entirely of mature B cells, and ob-
ained comparable results (data not shown).
To determine whether the decreased response of
-Myb-deficient B cells to soluble BLyS is likely related
o altered expression of BR3, we compared expression
f BR3 in c-Myb-deficient and control B cells. Expres-
ion of BR3 mRNA was decreased w50% in c-Myb-
eficient B cells, as was surface expression of BR3
Figures 6B and 6C), suggesting that the poor survival
f c-Myb-deficient peripheral B cells is related to de-
reased expression of BR3.
-Myb-Deficient B Cells Fail to Suppress Nuclear
ccumulation of PKC after BLyS Treatment
ignaling through BR3 has been reported to result in
ctivation of the alternative pathway of NF-κB signaling
Zarnegar et al., 2004), but we did not detect differ-
nces in either the amount of p100 processed or the
mount of p52 generated after BLyS treatment between
ontrol and c-Myb-deficient B cells (Figure S6). To de-
ermine whether loss of Myb led to defective expres-
ion of Bcl-2 family members after BLyS exposure, we
timulated control or c-Myb-deficient B cells with either
nti-CD40 or BLyS and examined Bcl-2 family member
xpression after 4 hr of treatment. Control and c-Myb-
eficient B cells specifically upregulated the expression
f A1 and Bcl-xL in response to anti-CD40 treatment
Figure S7A), but we did not detect increased A1 or Bcl-
L expression in mutant or control mice after treatment
ith BLyS (Figure S7B), consistent with recent reports
Trescol-Biemont et al., 2004; Zarnegar et al., 2004).
hus, c-Myb-deficient B cells appear to effectively acti-
ate the alternative NF-κB signaling pathway and regu-
ate expression of Bcl-2 family members.
Exposure of B cells to BLyS results in decreased
c-Myb in B Cell Development and Homeostasis
281Figure 4. c-Myb Is Not Essential for B Cell Proliferation In Vitro
(A) Histograms present 3[H]-thymidine uptake by purified CD43− B cells from f/d and control mice cultured for 48 hr in triplicate with no
treatment (NT), LPS, anti-CD40 plus IL-4, or anti-IgM. Error bars represent standard deviation of the mean (SD). Results are representative of
at least three independent experiments.
(B) Mybf and Mybd alleles were identified by Southern blotting at 0, 24, 48, and 72 hr after stimulation of purified CD43− B cells with LPS plus
IL-4. Results are representative of five independent experiments. f/w and w/d mice lacking CD19-cre are shown at the far left for comparison.
(C) CD43− purified B cells were stained with CFSE and cultured 96 hr in the presence of LPS plus IL-4. B220+ cells were analyzed for CFSE
fluorescence through a live lymphocyte gate. Dashed lines represent proliferating cells not stained with CFSE. Lower panels present the
upper panel histograms after MODFIT analysis. Results are representative of three independent experiments.
(D) Responder frequency was calculated for the histograms displayed in (C), as well as data from two other experiments. Error bars represent
SD of the mean for cells from 4 control and 3 f/f mice. *p < 0.002.
(E) Proliferative capacity was calculated for the histograms displayed in (C), as well as data from two other experiments. Error bars represent
SD of the mean for cells from 4 control and 3 f/f mice. *p < 0.005.
(F) Purified CD43− B cells were stimulated with LPS plus IL-4 for 24, 48, and 72 hr. Flow cytometry was used to assess propidium iodide (PI)
staining of B220+ cells without using a live cell gate.
(G) Histograms describe the percent of cells in G0/G1, S, G2/M, or with a Sub 2N DNA content. Error bars represent the SD of the mean from
6 control and 6 f/f mice. *p < 0.01.PKCδ accumulation in the nucleus, which prevents
spontaneous apoptosis in B cells (Mecklenbrauker et
al., 2004). Control and c-Myb-deficient B cells con-
tained similar amounts of PKCδ in the cytoplasm in the
presence or absence of BLyS (Figure 6D). After treat-
ment with BLyS for 24 hr, control B cells contained less
PKCδ in the nucleus compared to untreated cells (Fig-
ures 6D and 6E). However, in contrast to control B cells,
c-Myb-deficient B cells displayed little if any decrease
in the amount of nuclear PKCδ compared to untreated
cells (Figures 6D and 6E). These results suggest thatc-Myb-deficient B cells are hyporesponsive to BLyS at
least in part due to an inability to properly regulate
nuclear accumulation of PKCδ.
Discussion
c-Myb Is Critical during B Cell Development
in the BM
The size of the pro-B cell compartment did not differ
between f/f, f/d, and control mice, but the pre-B cell
compartment was decreased by w65% in the mutant
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(A) Scatter plot presenting the percent of TUNEL+CD19+ B cells and CD4+ or CD8+ T cells in freshly isolated splenocytes from f/d and control
mice. Each point represents a single mouse. *p < 0.01.
(B) TUNEL analysis of splenic CD43− B cells using Tdt TMR Red after being cultured 4 hr in complete medium (NT). Numbers indicate percent
of gated cells.
(C) TUNEL analysis of CD43− splenic B cells using Tdt TMR-Red after 4 hr of culture in complete medium with Z-VAD(OMe)-FMK. Numbers
indicate percent TUNEL+ cells.
(D) TUNEL+ splenic B cells after 4 hr of culture in complete growth medium with or without Z-VAD(OMe)-FMK. Each point represents a single
mouse. The percent of apoptotic c-Myb-deficient B cells was increased relative to control B cells. *p < 0.05.
(E) TUNEL+ purified B cells after 24 hr of culture in complete growth medium with or without Z-VAD(OMe)-FMK. Each point represents a
single mouse.
(F) CD43− splenic B cells were cultured in complete growth medium for 4 and 24 hr, then stained and analyzed by fluorescence microscopy.
f/d mice displayed an increase in the percentage of apoptotic B cells at 4 hr versus controls. *p < 0.05.mice. Analysis of BrdU uptake supported these obser-
vations, demonstrating that the lifespan of c-Myb-defi-
cient pro-B cells is similar to controls and that the same
number of pro-B cells is produced daily. However, the
production of new pre-B cells was decreased by 50%
in mutant mice as measured by BrdU uptake. Impor-
tantly, deletion at the Myb locus was quite efficient in
CD19+ pro-B cells but inefficient in pre-B cells. Taken
together, these data suggest that c-Myb activity is criti-
cal for the maintenance of pre-B cells. The block to
differentiation beyond the pro-B cell stage in f/f mice is
associated with a decrease in the number of Fr C# cells.
We note that the timing of the block during B cell devel-
opment in f/f mice is very similar to the block we have
reported during T cell development in c-Myb-deficient
T cells at the DN3 stage of differentiation (Bender et al.,
2004). Roles for c-Myb in at least three major processes
could explain the block during B cell development.
First, c-Myb has been reported to block differentiation
in several leukemic models of hematopoietic differenti-
ation (Oh and Reddy, 1999), and we considered the
possibility that in the absence of c-Myb pro-B cells
might differentiate more rapidly without completing re-
arrangement at the Igh locus. However, control and
c-Myb-deficient B cells exhibit similar residency times
within the pro-B, pre-B, and IM B cell stages as as-
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aessed by in vivo BrdU labeling, demonstrating that
oss of c-Myb does not result in more rapid differentia-
ion. Second, c-Myb may play a role in regulating the
fficiency of V(D)J recombination at the Igh locus. We
ave found that c-Myb is required for efficient recombi-
ation at the Tcrb locus (Bender et al., 2004), and
-Myb is reported to be necessary for efficient recombi-
ation at the Tcrd locus (Hernandez-Munain et al.,
996). However, we have not detected a decrease in
(D)J recombination at the Igh locus in f/f or f/d mice
ompared to controls (data not shown). Earlier Mybf de-
etion may reveal further roles for c-Myb at more imma-
ure stages of B cell development. Finally, c-Myb may
e required for the maintenance of C+ pre-B cells. Sig-
als through the pre-BCR and IL-7R are crucial during
his stage of B cell development. However, λ5 and
pre-B mRNA and protein expression as well as sur-
ace expression of IL-7R are equivalent in f/f and control
ro-B cells (data not shown). It remains possible that
-Myb may regulate expression of a downstream com-
onent of the pre-BCR or IL-7R signaling pathways.
-Myb and B Cell Homeostasis
espite greatly reduced production of IM B cells, f/d
ice contain nearly 50% the number of splenic B cells
s controls. This may be due to decreased BM output.
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Deficient B Cells
(A) Splenic CD43− B cells were cultured with either NT, IL-4, or rBLyS for 24, 48, 72, and 96 hr. CD19+ cells were then analyzed for uptake of
Topro-3 without using a live cell gate. Scatter plots present the percent of live (Topro-3−) B cells. *p < 0.005, **p < 0.001.
(B) Northern blot of BR3 mRNA in CD23+ splenic B cells. Histograms present mean and SD of the mean for samples normalized against
GAPD from a minimum of 3 mice.
(C) BR3 expression on CD23+ B cells. For controls (n = 7), the geometric mean of fluorescence was 163 ± 12, and for f/f and f/d mice (n = 9),
it was 113 ± 21. *p < 0.0005.
(D) Cytoplasmic and nuclear PKCδ was identified by immunoblotting in fresh c-Myb-deficient and control B cells (t = 0) or after 24 hr of NT
or rBLyS in vitro. Results are representative of three independent experiments.
(E) Amounts of nuclear PKCδ with or without rBLyS treatment in control and c-Myb-deficient B cells were determined by densitometry and
normalized by expression of Lamin-A. Percent of nuclear PKCδ after treatment with rBLyS versus after NT is presented. Histograms present
mean and SD for 3 control and 3 mutant mice. *p < 0.02.However, daily BM production exceeds the amount re-
quired to saturate the peripheral B cell pool (Forster
and Rajewsky, 1990), and 30% the normal number of
pre-B cells can support normal peripheral B cell num-
bers (Agenes et al., 1997). BM from f/f mice contains
w30% the normal number of pre-B cells, suggesting
that if c-Myb were only important for the BM pro-B to
pre-B transition, then cells that make it to the pre-B cell
stage should develop normally and provide a normal
number of peripheral B cells. Similar proportional BrdU-
labeling of control and mutant pre-B and IM B cells in-
dicates that their survival is normal in mutant mice.
Thus, it is most likely that the decreased production
of pre-B cells simply results in fewer IM B cells being
produced. However, Myb is poorly deleted in f/d pre-B
cells, suggesting that c-Myb plays a role during multi-
ple stages of B cell development in the BM.To determine whether c-Myb-deficient B cells prolif-
erate in response to a lymphopenic environment, we
adoptively transferred B cells lacking Myb into Rag1−/−
mice (Cabatingan et al., 2002). While fewer Myb-defi-
cient B cells were recovered compared to controls, a
significant portion of them proliferated as assessed by
CFSE dilution. This suggested that in the absence of
Myb, naive B cells, which comprise the majority of sple-
nic B cells, are defective in survival and/or proliferation.
However, in vitro proliferation assays indicate that
c-Myb is not essential for B cell proliferation per se. B
cells from f/f mice clearly underwent multiple rounds of
proliferation when stimulated with LPS plus IL-4, sug-
gesting that the loss of c-Myb limited the extent of pro-
liferation, consistent with a defect in survival. We ob-
served a comparable result when B cells from f/f mice
were stimulated with anti-IgM alone, yet Myb-deficient
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284B cells could be rescued from cell death by CD40 sig-
naling. Thus, increased Myb expression during prolifer-
ation does not appear to be required for cell-cycle pro-
gression in B cells, but instead appears to have another
function. Indeed, our results demonstrate that loss of
c-Myb results in an increase in the number of apoptotic
B cells in vivo and a decrease in the survival of freshly
isolated B cells. The increase in splenic B cell apopto-
sis in the absence of c-Myb appears to limit B cell ho-
meostatic expansion in f/f mice, resulting in a perpetu-
ally undersized splenic B cell compartment.
We observed decreased BR3 surface expression on
B cells lacking c-Myb, suggesting that the poor re-
sponse of c-Myb-deficient B cells to BLyS is likely re-
lated to decreased surface expression of BR3. Exami-
nation of BR3 signaling through the alternative NF-κB
pathway of p100 processing suggested that this path-
way is activated normally in c-Myb-deficient B cells. It
has been suggested that this pathway may regulate
Bcl-2 family expression (Mackay et al., 2003), but we
found that control and c-Myb-deficient B cells did not
respond to BLyS by upregulating antiapoptotic Bcl-2
family members. However, BLyS-induced survival me-
diated through the cytoplasmic sequestration of PKCδ
was defective in c-Myb-deficient B cells, suggesting
that regulation of PKCδ nuclear accumulation may be
more sensitive to the level of BR3 surface expression
than regulation of p100 processing. Alternatively, BR3
signaling may be intact in c-Myb-deficient B cells but
loss of c-Myb may prevent normal regulation of PKCδ
nuclear accumulation. Finally, although c-Myb-deficient
B cells do not respond to BLyS as well as control B
cells, they clearly are partially responsive to BLyS de-
spite defective regulation of PKCδ. This result suggests
that BLyS induces survival through multiple signaling
pathways, some of which may yet remain unknown.
Previous work reported that BCR signaling regulates
expression of BR3 (Smith and Cancro, 2003), which
suggested that the decreased BR3 expression on
c-Myb-deficient B cells may be related to defective
BCR signaling. However, BCR crosslinking of control
and c-Myb-deficient B cells had no significant effect on
BR3 surface expression, while both control and mutant
B cells upregulated BR3 in response to LPS (data not
shown). Thus, decreased BR3 expression on c-Myb-
deficient B cells does not appear to be related to ab-
normal BCR signaling. However, the defective response
of c-Myb-deficient B cells to BCR crosslinking may
contribute to the decreased number of peripheral B
cells in f/f and f/d mice, as induced loss of BCR expres-
sion or faulty BCR signaling result in the loss of most
peripheral B cells (Kraus et al., 2004; Lam et al., 1997).
Thus, the loss of c-Myb may affect multiple pathways
that regulate peripheral B cell homeostasis.
c-Myb and the Maintenance of Peripheral
B Cell Subsets
When mutations lead to the generation of a low number
of peripheral B cells, the B cells that are produced pref-
erentially move into the MZ compartment compared to
the FO compartment (Hao and Rajewsky, 2001; Pillai et
al., 2005). Martin and Kearney have speculated this
may be due to strong selective pressure to make a
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Pomplete repertoire of natural antibodies (Martin and
earney, 2002). Thus, perhaps not surprisingly, we
ound the number of MZ B cells is comparable in f/f
nd control mice, while the other peripheral B cell sub-
ets are decreased in number in mutant mice. Although
Z B cells are dependent on BLyS signaling for sur-
ival, there are comparable numbers of MZ B cells in
ontrol and BR3 heterozygous mice, which exhibit de-
reased BR3 surface expression (Sasaki et al., 2004).
ur results are similar, as we observe comparable num-
ers of MZ B cells in f/f and control mice despite de-
reased BR3 surface expression in c-Myb-deficient B
ells. Further, BR3-mediated signaling regulates ex-
ression of CD21 (Gorelik et al., 2004), and we also ob-
erve a decrease in CD21 expression on MZ B cells
rom f/f mice, similar to that reported in BLyS and BR3
nockout mice. Thus, despite comparable numbers of
Z B cells in f/f and control mice, loss of c-Myb does
ppear to affect other parameters of MZ B cell biology,
onsistent with decreased expression of BR3.
BLyS signaling is not necessary for maintenance of
1 B cells (Mackay et al., 2003), suggesting that the
oss of c-Myb-deficient B1 B cells may have a different
asis than the loss of splenic B cells in f/d mice. It is
ossible that B1 B cells have a greater requirement
han B2 B cells for c-Myb during development. Previ-
us work has demonstrated a relationship between
CR signaling strength and development of B1 B cells
Casola et al., 2004; Reichlin et al., 2004), and we have
ound that c-Myb-deficient B cells respond abnormally
o anti-IgM stimulation. This raises the possibility that
n the absence of c-Myb, impaired signaling through
he BCR may not be sufficient for the differentiation or
aintenance of B1 B cells.
xperimental Procedures
ice
ybf/w, Mybf/f, Mybf/d, and CD19-cre have been described (Bender
t al., 2004; Rickert et al., 1997). Rag1−/− mice (B6.129S7-
ag1tm1Mom) were purchased from Jackson Labs (Bar Harbor, ME).
ntibodies and Flow Cytometry
ingle-cell suspensions from 6- to 12-week-old mice were stained
ith fluorochrome- or biotin-conjugated antibodies as described
Bender et al., 2004). Cells were analyzed on a FACSCalibur or
ACSVantage cell sorter (BD Immunocytometry Systems, San
ose, CA) using a live lymphocyte gate unless otherwise stated.
ata were analyzed using CellQuest (BD Immunocytometry Sys-
ems) and FlowJo (Tree Star) software. Cell sorting was done on a
ACSVantage dual laser cell sorter.
Antibodies and reagents were purchased as follows. Caltag
Burlingame, CA): anti-B220-FITC (RA3-6B2), anti-CD4-APC (CT-
D4), and Streptavidin-PE-Cy7. eBioscience (San Diego, CA): anti-
gD-biotin (11-26). BD Pharmingen (San Diego, CA): anti-CD19-PE
1D3), anti-CD19-FITC (1D3), anti-CD19-biotin (1D3), anti-B220-
PC (RA3-6B2), anti-B220-PE (RA3-6B2), anti-BP-1-PE (6C3/BP-1),
nti-CD24-biotin (30-F1), anti-CD8a-APC (clone 53-6.7), anti-Kappa-
E (187.7), anti-CD43-biotin (S7), anti-CD43-PE (S7), anti-IgM-FITC
II/41), anti-IgM-APC (II/41), anti-BrdU-FITC (3D4), anti-BrdU-PE
3D4), anti-CD21-FITC (CD21/35), anti-CD23-PE (B3B4), Streptavi-
in-PerCP, and Streptavidin-FITC. Rabbit-anti-BR3 has been pre-
iously described (Sasaki et al., 2004). Zymed (San Francisco, CA):
oat-anti-rabbit-IgG-FITC.
emiquantitative RT-PCR
otal cellular RNA preparation, first-strand cDNA synthesis, and
CR for Myb and Actb were as described (Bender et al., 2004).
c-Myb in B Cell Development and Homeostasis
285Southern Blotting
Floxed, wild-type, and deleted Myb alleles were identified by DNA
blotting as 12.5 kb, 11.5 kb, and 10 kb fragments (Bender and
Kuehl, 1987).
BrdU Uptake
For BM analysis, mice received 0.6 mg BrdU (Sigma, St. Louis, MO)
in 200 l PBS intraperitoneally (IP) every 12 hr and were sacrificed
at 24, 48, or 72 hr. BM was harvested and stained for surface phe-
notype and BrdU incorporation as described (Allman et al., 1993).
The percentage of cells in each subset was determined by flow
cytometry and multiplied by the Osmond estimate of total marrow
cells (3 ×108) to determine the total number of cells in each subset
(Opstelten and Osmond, 1983). The percentage and number of
BrdU-labeled cells in each subset was then determined, the mean ±
SD were plotted as a function of time, and least squares regression
analysis was performed to obtain the turnover and production
rates.
For splenic analysis, mice received 1 mg BrdU in 100 l PBS IP
at 0 and 12 hr and were sacrificed at 24 hr. Incorporation of BrdU
into DNA was measured by flow cytometry using anti-BrdU-PE (BD
Pharmingen) per the manufacturer’s protocol.
Adoptive Transfer
Naive B cells were prepared using CD43 MACS beads (see below)
and labeled with CFSE (Molecular Probes) (Lyons and Parish,
1994). Cells were washed with PBS containing 0.5% BSA before
transfer. Unirradiated Rag1−/− recipients received 1.25 × 106 B cells
in 0.2 ml PBS injected into the lateral tail vein.
In Vitro Proliferation Assays
Splenic B cells were purified using MACS CD19, CD43, or Streptav-
idin MicroBeads (Miltenyi Biotec, Auburn, CA). CD19 beads were
used per the manufacturer’s protocol. With CD43 beads, single-
cell suspensions were first treated with a cocktail of biotinylated
antibodies (anti-CD3e, anti-CD11b, anti-GR-1, and anti-Ter119) fol-
lowed by CD43 and Streptavidin beads. For purification of CD23+
splenocytes, cells were first treated with anti-CD23-biotin (B3B4)
(eBioscience) and then positively selected using Streptavidin
beads. In each case, purity was >95%. Cells were resuspended in
RPMI 1640 with 5% FCS, 2 mM L-glutamine, and 50 M β-mercap-
toethanol (complete RPMI) and incubated at 37°C in a humidified
chamber with a 5% CO2 atmosphere. For [3H]-thymidine uptake
assays, 4 × 104 cells were cultured in 96-well plates at
2 × 105 cells/ml and stimulated with either 50 g/ml LPS (Sigma),
10 g/ml anti-CD40 (clone 3/23, BD Pharmingen) and 100 U/ml IL-4
(Pepro Tech, Rocky Hill, NJ), or 10 g/ml polyclonal anti-IgM (goat-
F(ab#)2 fragments, Fisher Scientific, Pittsburgh, PA). 6 hr before
harvesting, 1 Ci of [3H]-thymidine was added to each well. Cells
were collected onto Filtermat A filters (PerkinElmer Life Sciences,
Boston, MA) and analyzed on a MicroBeta Trilux scintillation
counter (PerkinElmer Life Sciences).
B cells were labeled with CFSE and stimulated with LPS (50 g/
ml) and IL-4 (100 U/ml) using 5 × 105 B cells cultured at 5 × 105
cells/ml, and the results were analyzed using MODFIT (Verity Soft-
ware House, Topsham, ME). Precursor frequency and proliferative
capacity were calculated as described (Gudmundsdottir et al.,
1999). DNA content was examined by staining with Propidium Io-
dide (PI) (Molecular Probes) and analyzed using MODFIT.
Survival Assays
TUNEL was performed using the In Situ Cell Death Detection Kit,
TMR red (Roche, Indianapolis, IN) on freshly isolated spleen cells
or 106 purified CD43− B cells cultured at 106 cells/ml in complete
RPMI. For differential uptake analysis of apoptotic cells, 106 puri-
fied CD43− B cells were stained with Hoechst 33342 (Molecular
Probes) and PI and analyzed as described (Lee and Shacter, 2001)
on a Leica epiflourescent microscope using a UV filter cube with
Isee imaging software (Inovision, Raleigh, NC). For the pan-cas-
pase inhibitor assay, 106 purified CD43− B cells were cultured in
complete RPMI at 106 cells/ml with no treatment (NT) or with 40
M Z-VAD(OMe)-FMK (ICN Pharmaceuticals, Aurora, OH). For BLyS
survival assays, 106 purified CD43− B cells were cultured in com-plete RPMI at 106 cells/ml with NT, 100 U/ml IL-4, or 50 ng/ml rBLyS
(Human Genome Sciences; kindly provided by Michael P. Cancro).
For Topro-3 (Molecular Probes) staining, cells were stained with
anti-CD19-PE, washed in PBA, and incubated for 5 min with 1 nm
Topro-3.
Northern Blotting
Total cellular RNA was prepared from 107 purified CD23+ spleno-
cytes using the RNeasy Mini Kit (Qiagen, Valencia, CA), fraction-
ated by formaldehyde gel electrophoresis, transferred to nitrocellu-
lose, and hybridized with radiolabeled cDNA probes encoding
mouse BR3 and GAPDH (Bender and Kuehl, 1987).
Immunoblotting
Cytosolic and nuclear lysates were prepared as previously de-
scribed (Mecklenbrauker et al., 2004). Protein (10 g) was fraction-
ated on 8% acrylamide gels, transferred to nitrocellulose, and incu-
bated with anti-PKCδ (Santa Cruz), mouse-anti-Tubulin (Sigma), or
rabbit-anti-Lamin A/C (Cell Signaling), followed by the appropriate
HRP-conjugated antibody (Amersham, Piscataway, NJ). Blots were
developed using enhanced chemiluminescence (Amersham).
Supplemental Data
Supplemental Data include seven figures and two tables and can
be found with this article online at http://www.immunity.com/cgi/
content/full/23/3/275/DC1/.
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